Innovation and Enterprise Unit

We are continuously seeking partners from industry across all areas of our research. Below you will find the areas in which we are currently actively seeking partners.

Materials available for use/licencing

  • Fleming’s proprietary transgenic mouse models.

Patented Technology available for licencing/co-development

  • Non-TNF assay for Rheumatoid Arthritis.


  • Customised Assay Design.
  • in-vivo biotinylation tagging.

On-Going Research Programs

  • The study of cognitive decline and development of early interventions to cognitive disorder in Drosophila, focussing on tauopathies (Alzheimers, Parkinsons) and fragile X syndrome (ADHD, age related cognitive decline).
  • Role of Autotaxin in inflammation, respiratory disease and cancer.
  • Role of RANKL in bone metabolism, and the development of mice models for the study of metabolic bone disease.
  • Post-transcriptional regulators in inflammation and cancer, specifically the RNA-binding proteins HuR and AUF-1, with associated mouse models of inflammation and cancer.
  • Bone Morphogenetic Proteins in tissue repair and regeneration, primarily in lung and liver fibrosis.
  • Epigenetics of Cancer – use of Set9 and Smyd3 mouse models to study histone methylase function in cancer.
  • Epigenetics of de novo Methyltransferases in colon cancer.
  • Epigenetics of metabolic disease.
  • Development of Novel Stem Cell Technologies for Therapeutics.

For further information about any of these or other areas of our research, please contact us directly.